James W Schurr, Lara Ambrosi, Jillian Fitzgerald, Christian Bermudez, Michael V Genuardi, Mark Brahier, Tonya Elliot, Kevin McGowan, Akram Zaaqoq, Sonjoy Laskar, Stuart M Pope, Michael M Givertz, Hari Mallidi, Katelyn W Sylvester, Frank C Seifert, Allison J McLarty
BACKGROUND: The efficacy of extracorporeal membrane oxygenation (ECMO) as a bridge to left ventricular assist device (LVAD) remains unclear, and recipients of the more contemporary HeartMate 3 (HM3) LVAD are not well represented in previous studies. We therefore undertook a multicenter, retrospective study of this population. METHODS AND RESULTS: INTERMACS 1 LVAD recipients from five U.S. centers were included. In-hospital and one-year outcomes were recorded. The primary outcome was the overall mortality hazard comparing ECMO versus non-ECMO patients by propensity-weighted survival analysis...
March 8, 2024: Artificial Organs